Prelude Therapeutics Inc·4

Mar 2, 4:06 PM ET

Lim Bryant David 4

4 · Prelude Therapeutics Inc · Filed Mar 2, 2023

Insider Transaction Report

Form 4
Period: 2023-03-01
Lim Bryant David
CLO, CFO, Corp Sec.
Transactions
  • Award

    Employee Stock Option (Right to Buy)

    2023-03-01+250,000250,000 total
    Exercise: $5.93Exp: 2033-02-28Common Stock (250,000 underlying)
Footnotes (1)
  • [F1]The stock option vests as to 25% of the total shares on March 1, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Documents

1 file
  • 4
    primarydocument.xmlPrimary

    PRIMARY DOCUMENT